These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25908996)

  • 21. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    Farmaki PF; Chini MC; Mangafas NM; Tzanoudaki MT; Piperi CP; Lazanas MZ; Spoulou VS
    J Infect Dis; 2018 Jun; 218(1):26-34. PubMed ID: 29722823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies.
    Lue C; Tarkowski A; Mestecky J
    J Immunol; 1988 Jun; 140(11):3793-800. PubMed ID: 3372993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.
    Kroon FP; Rimmelzwaan GF; Roos MT; Osterhaus AD; Hamann D; Miedema F; van Dissel JT
    AIDS; 1998 Dec; 12(17):F217-23. PubMed ID: 9863863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.
    Rodriguez-Barradas MC; Alexandraki I; Nazir T; Foltzer M; Musher DM; Brown S; Thornby J
    Clin Infect Dis; 2003 Aug; 37(3):438-47. PubMed ID: 12884170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.
    Bahuaud M; Beaudouin-Bazire C; Husson M; Molto A; Launay O; Batteux F; Dougados M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1464-1470. PubMed ID: 29432051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.
    Ohshima N; Nagai H; Matsui H; Akashi S; Makino T; Akeda Y; Oishi K
    Vaccine; 2014 Feb; 32(10):1181-6. PubMed ID: 24120483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy.
    D'Orsogna LJ; Krueger RG; McKinnon EJ; French MA
    AIDS; 2007 Aug; 21(13):1747-52. PubMed ID: 17690573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
    Lao-Araya M; Puthanakit T; Aurpibul L; Taecharoenkul S; Sirisanthana T; Sirisanthana V
    Vaccine; 2011 May; 29(23):3977-81. PubMed ID: 21473954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up.
    Hejdeman B; Leandersson AC; Fredriksson EL; Sandström E; Wahren B; Bratt G
    HIV Med; 2003 Apr; 4(2):101-10. PubMed ID: 12702130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response.
    Rodriguez-Barradas MC; Groover JE; Lacke CE; Gump DW; Lahart CJ; Pandey JP; Musher DM
    J Infect Dis; 1996 Jun; 173(6):1347-53. PubMed ID: 8648206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.